AVITA MEDICAL INC

AVITA MEDICAL Q2‑2026: $21.7M revenue up $1.61M, operating loss shrinks, and breakeven path accelerates, boosting confidence in its burns & chronic wound pipeline.

Avita Medical’s board reshuffle and modest stock rebound hint at untapped potential in its burn and wound‑care therapies, yet the stock remains heavily discounted.

Avita Medical’s board reshuffle, adding veteran med‑tech exec Joe Woody, signals a push to commercialize its wound‑care platform amid a modest stock rally and mixed analyst views.